Global Alzheimer’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035
Global
Alzheimer’s Disease Market Outlook
Thelansis’s “Global
Alzheimer’s Disease Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease
overview, epidemiology, kidney biopsy cases, drug utilization, prescription
share analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under the
potential IgA Nephropathy treatment modalities options for the 32 markets
(North America, Europe, Middle East, Asia Pacific, Africa, South / Latin
America).
Alzheimer’s
Disease Overview
Alzheimer’s
disease (AD) is the foremost cause of dementia, accounting for approximately
60% to 80% of all cases of dementia. This condition is a progressive and
neurodegenerative ailment characterized by three principal features within the
brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of
neurons, and fragments of other nerve cells; neurofibrillary tangles (NFTs),
knotted bundles of fibers containing clusters of a protein known as tau
situated within neurons; and the deterioration of connections between neurons,
which leads to memory and learning deficits. Alzheimer’s disease exhibits
distinctive brain alterations (pathology) distinct from those of other causes
of dementia, such as Lewy body disease or cerebrovascular disease. When these
coexisting pathologies are identified during a person’s lifetime, it is called
mixed dementia.
Market Definition:
- North America
(United States, Canada)
- Europe
(Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany,
Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain,
Sweden, Switzerland, United Kingdom)
- Middle East
(Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific
(Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New
Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt,
Nigeria, South Africa, Morocco)
- South / Latin
America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across the 32
markets (North America, Europe, Middle East, Asia Pacific, Africa, South /
Latin America)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment